News Molecure S.A.

Equities

MOC

PLONCTH00011

Market Closed - Warsaw S.E. Other stock markets 11:55:42 2024-05-15 EDT			5-day change	1st Jan Change
14.72 ^PLN	-4.29%		+1.66%	-24.51%

03-22	Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis	CI
01-16	Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis	03-22	CI
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I	01-16	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment	23-07-24	MT
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01	23-07-24	CI
Molecure S.A. announced that it has received PLN 49.968 million in funding	23-07-20	CI
Poland's Molecure Files Investigational New Drug Application with US FDA for Pulmonary Sarcoidosis Drug	23-06-23	MT
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Poland's Molecure Doses First Patient in Cancer Treatment Trial	23-03-08	MT
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer	23-03-08	CI
Molecure S.A. Announces Management Changes	23-01-03	CI
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022	22-12-06	AQ
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland	22-11-28	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-30	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-28	CI
Molecure S.A.(WSE:MOC) dropped from S&P Global BMI Index	22-09-19	CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
ONCOARENDI THERAPEUTICS S.A will Change its Name to Molecure S.A	22-04-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Molecure S.A.

Equities

MOC

PLONCTH00011

Summary

Filters